Maculopathie causée par le polysulfate de pentosane : Restez à l’affût de cette affection trompeuse
Résumé
Le polysulfate de pentosane sodique (PPS) (Elmiron; Janssen Pharmaceuticals), un médicament utilisé pour traiter les douleurs et l’inconfort de la vessie associés à la cystite interstitielle (CI), a été associé à une maculopathie distinctive mettant en danger la vue des patients. Comme dans le cas de la maculopathie causée par l’hydroxychloroquine, l’ophtalmologiste généraliste se doit de connaître cette affection potentiellement évitable. Dans le présent article, nous résumerons brièvement les données probantes appuyant cette association, nous passerons en revue les manifestations cliniques de la maculopathie causée par le PPS et nous fournirons quelques conseils concernant les protocoles de dépistage.
Références
Pearce WA, Chen R, Jain N. Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium. Ophthalmology. Nov 2018;125(11):1793-1802. doi:10.1016/j.ophtha.2018.04.026
Interstitial Cystitis (Painful Bladder Syndrome). National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). July 2017. Available at https://www.niddk.nih.gov/health-information/urologic-diseases/interstitial-cystitis-painful-bladder-syndrome/definition-facts. Accessed 23 January 2022.
Nickel JC, Teichman JM, Gregoire M, Clark J, Downey J. Prevalence, diagnosis, characterization, and treatment of prostatitis, interstitial cystitis, and epididymitis in outpatient urological practice: the Canadian PIE Study. Urology. Nov 2005;66(5):935-40. doi:10.1016/j.urology.2005.05.007
Janssen Pharmaceuticals. Elmiron (pentosan polysulfate sodium) [package insert]. U.S. Food and Drug Administration. March 2021. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020193s014lbl.pdf. Accessed 5 January 2022.
Elmiron – intravescial instillation. Janssen Pharmaceuticals. 5 April 2021. Available at https://www.janssenmd.com/elmiron/dosage-and-administration/administration-routes/elmiron-intravesical-instillation?disclaimer&tid=171990374961d5dfcf3abf47.64211558. Accessed 5 January 2022.
Lindeke-Myers A, Hanif AM, Jain N. Pentosan polysulfate maculopathy. Surv Ophthalmol. Jan-Feb 2022;67(1):83-96. doi:10.1016/j.survophthal.2021.05.005
Hanif AM, Shah R, Yan J, et al. Strength of Association between Pentosan Polysulfate and a Novel Maculopathy. Ophthalmology. Oct 2019;126(10):1464-1466. doi:10.1016/j.ophtha.2019.04.024
Vora RA, Patel AP, Melles R. Prevalence of Maculopathy Associated with Long-Term Pentosan Polysulfate Therapy. Ophthalmology. Jun 2020;127(6):835-836. doi:10.1016/j.ophtha.2020.01.017
Wang D, Au A, Gunnemann F, et al. Pentosan-associated maculopathy: prevalence, screening guidelines, and spectrum of findings based on prospective multimodal analysis. Can J Ophthalmol. Apr 2020;55(2):116-125. doi:10.1016/j.jcjo.2019.12.001
Higgins K, Welch RJ, Bacorn C, et al. Identification of Patients with Pentosan Polysulfate Sodium-Associated Maculopathy through Screening of the Electronic Medical Record at an Academic Center. J Ophthalmol. 2020;2020:8866961. doi:10.1155/2020/8866961
Philip AM, Wannamaker KW, Miller DM. Prevalence and Dose Dependency Analysis of Pentosan Polysulfate Sodium Maculopathy. Ophthalmic Epidemiol. Jan 26 2022:1-6. doi:10.1080/09286586.2022.2031227
Kalbag NS, Maganti N, Lyon AT, Mirza RG. Maculopathy Secondary to Pentosan Polysulfate Use: A Single-Center Experience. Clin Ophthalmol. 2021;15:513-519. doi:10.2147/opth.S285013
Leung EH, Sharma S, Levie-Sprick A, Lee GD, Cho H, Mukkamala K. Pentosan Polysulfate Sodium-Associated Pigmentary Retinopathy: Risk Factors and Fundus Findings. Clin Ophthalmol. 2021;15:4809-4816. doi:10.2147/opth.S340041
Jain N, Li AL, Yu Y, VanderBeek BL. Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort. Br J Ophthalmol. Aug 2020;104(8):1093-1097. doi:10.1136/bjophthalmol-2019-314765
Ludwig CA, Vail D, Callaway NF, Pasricha MV, Moshfeghi DM. Pentosan Polysulfate Sodium Exposure and Drug-Induced Maculopathy in Commercially Insured Patients in the United States. Ophthalmology. Apr 2020;127(4):535-543. doi:10.1016/j.ophtha.2019.10.036
VanderBeek BL, Jain N. Re: Ludwig et al.: Pentosan polysulfate sodium exposure and drug-induced maculopathy in commercially insured patients in the United States (Ophthalmology. 2020;127:535-543). Ophthalmology. May 2020;127(5):e35-e36. doi:10.1016/j.ophtha.2020.01.004
Jain N, Liao A, Garg SJ, et al. Expanded Clinical Spectrum of Pentosan Polysulfate Maculopathy: A Macula Society Collaborative Study. Ophthalmol Retina. Mar 2022;6(3):219-227. doi:10.1016/j.oret.2021.07.004
Lyons RJ, Brower J, Jain N. Visual Function in Pentosan Polysulfate Sodium Maculopathy. Invest Ophthalmol Vis Sci. Nov 2 2020;61(13):33. doi:10.1167/iovs.61.13.33
Hanif AM, Armenti ST, Taylor SC, et al. Phenotypic Spectrum of Pentosan Polysulfate Sodium-Associated Maculopathy: A Multicenter Study. JAMA Ophthalmol. Nov 1 2019;137(11):1275-1282. doi:10.1001/jamaophthalmol.2019.3392
Barnes AC, Hanif AM, Jain N. Pentosan Polysulfate Maculopathy versus Inherited Macular Dystrophies: Comparative Assessment with Multimodal Imaging. Ophthalmol Retina. Dec 2020;4(12):1196-1201. doi:10.1016/j.oret.2020.05.008
Christiansen JS, Barnes AC, Berry DE, Jain N. Pentosan polysulfate maculopathy versus age-related macular degeneration: comparative assessment with multimodal imaging. Can J Ophthalmol. Feb 2022;57(1):16-22. doi:10.1016/j.jcjo.2021.02.007
Mishra K, Patel TP, Singh MS. Choroidal Neovascularization Associated with Pentosan Polysulfate Toxicity. Ophthalmol Retina. Jan 2020;4(1):111-113. doi:10.1016/j.oret.2019.08.006
Abou-Jaoude MM, Davis AM, Fraser CE, et al. New Insights Into Pentosan Polysulfate Maculopathy. Ophthalmic Surg Lasers Imaging Retina. Jan 1 2021;52(1):13-22. doi:10.3928/23258160-20201223-04
De Larochellière E, Bourgault S. Pentosan polysulfate sodium-induced pigmentary maculopathy with non-leaking cystoid macular edema successfully treated with anti-VEGF therapy. Retin Cases Brief Rep. Jun 5 2020. doi:10.1097/icb.0000000000001013
Shah R, Simonett JM, Lyons RJ, Rao RC, Pennesi ME, Jain N. Disease Course in Patients With Pentosan Polysulfate Sodium-Associated Maculopathy After Drug Cessation. JAMA Ophthalmol. Aug 1 2020;138(8):894-900. doi:10.1001/jamaophthalmol.2020.2349
Wang J, Ying GS. Growth Rate of Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Meta-Analysis of Natural History Studies and Implications for Designing Future Trials. Ophthalmic Research. 2021;64(2):205-215. doi:10.1159/000510507
Barnett JM, Jain N. Potential new onset clinically detectable pentosan polysulfate maculopathy years after drug cessation. Retin Cases Brief Rep. Nov 17 2020. doi:10.1097/icb.0000000000001090
Huckfeldt RM, Vavvas DG. Progressive Maculopathy After Discontinuation of Pentosan Polysulfate Sodium. Ophthalmic Surg Lasers Imaging Retina. Oct 1 2019;50(10):656-659. doi:10.3928/23258160-20191009-10
Publié
Comment citer
Numéro
Rubrique
Licence
© Canadian Eye Care Today 2022
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
